195 related articles for article (PubMed ID: 31132796)
1. Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
Scherbaum N; Holzbach R; Stammen G; Kirchof U; Bonnet U
Pharmacopsychiatry; 2020 Jan; 53(1):37-39. PubMed ID: 31132796
[TBL] [Abstract][Full Text] [Related]
2. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
3. The Prescription of Anticraving Medication and its Economic Consequences.
Holzbach R; Stammen G; Kirchhof U; Scherbaum N
Eur Addict Res; 2019; 25(5):224-228. PubMed ID: 31216535
[TBL] [Abstract][Full Text] [Related]
4. [Use of drugs for alcohol use disorder in Norway 2004–16].
Heldal AT; Skurtveit S; Lobmaier PPK; Vederhus JK; Bramness JG
Tidsskr Nor Laegeforen; 2018 Nov; 138(18):. PubMed ID: 30421743
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Harris AHS; Ellerbe L; Reeder RN; Bowe T; Gordon AJ; Hagedorn H; Oliva E; Lembke A; Kivlahan D; Trafton JA
Psychol Serv; 2013 Nov; 10(4):410-419. PubMed ID: 23356858
[TBL] [Abstract][Full Text] [Related]
6. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
7. National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
Morley KC; Logge W; Pearson SA; Baillie A; Haber PS
Drug Alcohol Depend; 2016 Sep; 166():254-7. PubMed ID: 27394934
[TBL] [Abstract][Full Text] [Related]
8. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacotherapy of alcohol withdrawal: update and new developments].
Soyka M; Rösner S
Nervenarzt; 2021 Jan; 92(1):57-65. PubMed ID: 32696076
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
12. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
13. Physicians' opinions about medications to treat alcoholism.
Mark TL; Kranzler HR; Song X; Bransberger P; Poole VH; Crosse S
Addiction; 2003 May; 98(5):617-26. PubMed ID: 12751979
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India.
Basu D; Jhirwal OP; Mattoo SK
Am J Addict; 2005; 14(4):381-95. PubMed ID: 16188718
[TBL] [Abstract][Full Text] [Related]
15. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
[TBL] [Abstract][Full Text] [Related]
16. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
17. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
18. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Mason BJ
J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
[TBL] [Abstract][Full Text] [Related]
19. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M; Chick J
Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
